Technology
Health
Pharmaceutical

Eagle Pharmaceuticals

$48.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.27 (2.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EGRX and other stocks, options, ETFs, and crypto commission-free!

About

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. Read More The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Employees
96
Headquarters
Woodcliff Lake, New Jersey
Founded
2007
Market Cap
673.72M
Price-Earnings Ratio
23.02
Dividend Yield
0.00
Average Volume
233.78K
High Today
$48.89
Low Today
$46.66
Open Price
$47.21
Volume
40.13K
52 Week High
$85.66
52 Week Low
$36.03

Collections

Technology
Health
Pharmaceutical
Alcohol
Beverages
Food
2014 IPO
US

News

TradingNewsNowMar 21

Recent Performance: Eagle Pharmaceuticals (NASDAQ: EGRX)

Eagle Pharmaceuticals trades as part of the healthcare sector and trades as part of the drug manufacturers industry. The company CEO is Scott L. Tarriff. Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Previous Intraday Trading Performance: The EGRX stock showed a previous change of -1.97% with an open at 48.87 and a close of 47.89. It reached an intraday high of 49.36...

4
Yahoo FinanceFeb 21

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on higher revenues when Eagle Pharmaceuticals (EGRX) reports results for the quarter ended December 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

1

Earnings

$0.49
$0.73
$0.98
$1.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.